Skip to main content
. 2011 Jan 22;20(1):107–117. doi: 10.1007/s00520-010-1073-9

Table 1.

NCCN antiemesis guidelines[1]

Chemotherapy Antiemetics
Acute CINV (day 1)
 High risk 5HT3-antagonist + dexamethasone + aprepitant
 Moderate risk 5HT3-antagonist + dexamethasone + aprepitant in selected patientsa
 Low risk dexamethasone or metoclopramide or prochlorperazine
 Minimal risk No antiemetics
Delayed CINV
 High risk Dexamethasone (days 2–4) + aprepitant (days 2–3) + lorazepam in selected patients
 Moderate risk Dexamethasone (days 2–4) + aprepitant if used on day 1 (days 2–3)a or 5HT3-antagonist (days 2–4) + lorazepam in selected patients
 Low en minimal risk No antiemetics

aAprepitant should be added to dexamethasone and a 5-HT3 antagonist for patients receiving the combination of an anthracycline and cyclophosphamide and selected patients receiving other chemotherapies of moderate emetic risk (e.g., carboplatin, doxorubicin, epirubicin, ifosfamide, irinotecan, methotrexate)